BIGT:LSE:LSE-L&G Pharma Breakthrough UCITS ETF (GBX)

ETF | Others |

Last Closing

USD 778

Change

+6.95 (+0.90)%

Market Cap

USD 0.03B

Volume

2.27K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R15:LSE SoftBank Group Corp.

+179.00 (+2.35%)

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

+243.00 (+3.28%)

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

+7.75 (+4.53%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+52.70 (+6.49%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.15 (+1.13%)

USD 617.54B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.14 (+0.84%)

USD 617.54B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

+21.75 (+1.09%)

USD 348.03B
0QZK:LSE Coca-Cola Co.

+0.10 (+0.16%)

USD 266.08B
0QZO:LSE 0QZO

+0.30 (+0.27%)

USD 258.54B

ETFs Containing BIGT:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.39% 9% A- 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.39% 9% A- 23% F
Trailing 12 Months  
Capital Gain -14.40% 8% B- 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.40% 8% B- 22% F
Trailing 5 Years  
Capital Gain -0.20% 30% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.20% 24% F 38% F
Average Annual (5 Year Horizon)  
Capital Gain 3.19% 49% F 56% F
Dividend Return 3.19% 49% F 55% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.57% 54% F 68% D+
Risk Adjusted Return 23.51% 51% F 63% D
Market Capitalization 0.03B 26% F 25% F

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.